High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*.
Saved in:
| Title: | High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*. |
|---|---|
| Authors: | Westphal, D.1,2 (AUTHOR) dana.westphal@uniklinikum-dresden.de, Garzarolli, M.1 (AUTHOR), Sergon, M.3 (AUTHOR), Horak, P.4,5 (AUTHOR), Hutter, B.4,6,7 (AUTHOR), Becker, J.C.8,9 (AUTHOR), Wiegel, M.1 (AUTHOR), Maczey, E.10 (AUTHOR), Blum, S.11 (AUTHOR), Grosche‐Schlee, S.12 (AUTHOR), Rütten, A.13 (AUTHOR), Ugurel, S.8 (AUTHOR), Stenzinger, A.4,14 (AUTHOR), Glimm, H.15,16,17,18 (AUTHOR), Aust, D.2,3,19 (AUTHOR), Baretton, G.2,3,19 (AUTHOR), Beissert, S.1,2 (AUTHOR), Fröhling, S.4,5 (AUTHOR), Redler, S.20 (AUTHOR), Surowy, H.20 (AUTHOR) |
| Source: | British Journal of Dermatology. Dec2021, Vol. 185 Issue 6, p1186-1199. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
